<DOC>
	<DOC>NCT00492869</DOC>
	<brief_summary>Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.</brief_summary>
	<brief_title>Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion: Male and female patients of any race 18 years or older Adult recipients of kidney transplant from a deceased or living donor Recipients of a functioning kidney within 24 hours post transplant Exclusion: Need for medication prohibited by the protocol Patients or donors infected with Hepatitis B,C or HIV Patients with a history of cancer within last 5 years Patients with history of significant cardiac disorder Patients of highrisk immunological status Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>rejection</keyword>
	<keyword>AEB071</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>mycophenolic</keyword>
	<keyword>basiliximab</keyword>
	<keyword>immunosuppression</keyword>
</DOC>